SBP Group CEO Eric Tse discusses his outlook for China's healthcare sector and how one of China's old-guard pharmaceutical players aims to transition from generics focused model to drug development. He speaks with Stephen Engle from the sidelines of 'The World Economic Forum's Annual Meeting of the New Champions' in Dalian. (Source: Bloomberg)
SBP Group CEO Eric Tse discusses his outlook for China's healthcare sector and how one of China's old-guard pharmaceutical players aims to transition from generics focused model to drug development. He speaks with Stephen Engle from the sidelines of 'The World Economic Forum's Annual Meeting of the New Champions' in Dalian. (Source: Bloomberg)
<iframe src="https://statesidedaily.com/embed/cluster/9b31fe0cf460f85773af826653725e6a6736e6de" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="SBP Group Eyes Innovation as It Shifts Beyond Generics"></iframe>
